Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CALVIDEX-CT is a fixed-dose combination pharmaceutical product marketed by Dexon Biotech, primarily indicated for the treatment and prevention of calcium and vitamin D deficiencies, osteoporosis, and bone-related disorders. It contains **calcitriol**, the physiologically active form of vitamin D3, which acts as a ligand for the vitamin D receptor (VDR) to enhance intestinal calcium absorption and renal calcium reabsorption. **Calcium carbonate** serves as a high-elemental calcium source for bone mineralization. **Zinc** is included as an essential trace element that supports osteoblast activity and collagen synthesis. This formulation is widely used in the management of postmenopausal osteoporosis and secondary hyperparathyroidism in patients with chronic kidney disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcitriol + calcium carbonate + zinc (Dexon Biotech).